Delirium in older patients after surgery may lead to long-term cognitive decline

BOSTON, USA ( July 14, 2016 ) — Researchers from the Harvard Medical School – affiliated Hebrew SeniorLife Institute for Aging Research (IFAR) have found increasing evidence that delirium in older surgical patients may be associated with long-term cognitive decline. Findings from the study were published today in the July 2016 issue of Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association.

Delirium is a common, serious, often fatal disorder affecting as many as 50% of older people during the course of surgery or hospitalization and costs more than $164 billion per year. However, until now, the relationship between delirium and long-term cognitive decline has not been well-explored. The Hebrew SeniorLife IFAR study, conducted in collaboration with Beth Israel Deaconess Medical Center, Brown University, and Northeastern University examined the trajectory of short-term and long-term cognitive decline in patients who experienced delirium for 36 months following a surgery.

Delirium occurred in 134 of the original 560 participants in the study. Both groups of participants, those who experienced delirium and those who did not, showed a significant cognitive decline at one month, followed by a recovery above baseline at two months and then a gradual decline for the next 34 months. The 560 participants in the study were aged 70 years or older, had no previous signs of dementia, and were scheduled to undergo surgery with an anticipated length stay in the hospital of three days or greater.

The delirium group, however, had a significantly greater decline at one month compared to those without delirium. Although they too recovered at two months, this group had a more significant decline after the two- month mark than the non-delirium group. Beyond two months, both groups declined on average, but the delirium group declined significantly more. When researchers compared changes from baseline to 36 months, there was no significant change for the group who did not experience delirium, but a marked decline for those who did.

According to the researchers, the fact that both the delirium and non-delirium groups suffered cognitive decline at month one, and then a return to baseline at month two, likely represents the immediate impact of events such as anesthesia, surgery, and hospitalization. However, the higher rate of cognitive decline after month one for those with delirium suggests that delirium may set off a cascade of events which leads to progressive, long-lasting effects. Or, it is alternatively possible that delirium is associated with a pre-existing higher rate of cognitive decline that is not detectable at baseline. In either case, delirium may serve as a marker for seniors with poor cognitive reserve.

"This study is highly significant in demonstrating that delirium is associated with subsequent long-term cognitive decline at a pace similar to that of mild cognitive impairment, even in those with normal cognitive function at baseline," says Sharon K. Inouye, M.D., M.P.H., Director of the Aging Brain Center at the Institute for Aging Research, Hebrew SeniorLife, a faculty member in the Division of Gerontology at Beth Israel Deaconess Medical Center, and Professor of Medicine at Harvard Medical School. "Whether or not delirium is causative, it identifies those at risk for subsequent cognitive decline and warrants both close clinical follow-up and preventive interventions."

A total of 560 participants underwent a baseline assessment and medical review 30 days before surgery to ascertain their normal cognitive status. After surgery, participants were regularly assessed for up to 36 months. The delirium assessment during hospitalization included brief cognitive testing and interviews with family and nurses conducted daily. Delirium was rated using a standardized approach with high sensitivity. Cognitive performance was assessed using a comprehensive neuropsychological test battery which was administered before surgery and with each follow-up.

The study was funded by the National Institutes of Health (Grant No. P01AG031720 to Dr. Sharon Inouye)

About the Institute for Aging Research

Scientists at the Institute for Aging Research seek to transform the human experience of aging by conducting research that will ensure a life of health, dignity and productivity into advanced age. The Institute carries out rigorous studies that discover the mechanisms of age-related disease and disability; lead to the prevention, treatment and cure of disease; advance the standard of care for older people; and inform public decision-making. The Aging Brain Center within IFAR studies cognitive aging and conditions affecting brain health.

About Hebrew SeniorLife

Hebrew SeniorLife, an affiliate of Harvard Medical School, is a national senior services leader uniquely dedicated to rethinking, researching and redefining the possibilities of aging. Based in Boston, the non-profit, non-sectarian organization has provided communities and health care for seniors, research into aging, and education for geriatric care providers since 1903. For more information about Hebrew SeniorLife, visit , follow us on Twitter @H_SeniorLife, like us on Facebook or read our blog.

About Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association

Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association focuses on the scientific, medical and practical care issues for researchers and practitioners. Coverage extends from healthy brain aging to all forms of dementia and includes original peer-reviewed articles detailing clinical research advances as well as conference reports and abstracts. Specific areas of coverage include developments in early detection, intervention, prevention, and application of new technologies in health services.

Hebrew SeniorLife Institute for Aging Research , 14.07.2016 (tB).


New guidance to prevent the tragedy of unrecognized esophageal intubation
Overly restrictive salt intake may worsen outcomes for common form…
COVID-19 vaccines are estimated to have prevanented 20 million deaths…
Novel sleep education learning modules developed for nurse practitioners
Scientists discover how salt in tumours could help diagnose and…


Aktuelle Versorgungssituation der Opioidtherapie im Fokus
Individuelle Schmerztherapie mit Opioiden: Patienten im Mittelpunkt
Versorgung verbessern: Deutsche Gesellschaft für Schmerzmedizin fordert die Einführung des…
Pflegeexpertise im Fokus: Schmerzmanagement nach Operationen
Versorgung verbessern: Bundesweite Initiative der Deutschen Gesellschaft für Schmerzmedizin zu…


Menschen mit Diabetes während der Corona-Pandemie unterversorgt? Studie zeigt auffällige…
Suliqua® zur Therapieoptimierung bei unzureichender BOT
„Wissen was bei Diabetes zählt: Gesünder unter 7 PLUS“ gibt…
Kaltplasma bei diabetischem Fußsyndrom wirkt via Wachstumsfaktoren
Typ-1-Diabetes: InRange – auf die Zeit im Zielbereich kommt es…


Gesunde Ernährung: „Nicht das Salz und nicht das Fett verteufeln“
Mangelernährung gefährdet den Behandlungserfolg — DGEM: Ernährungsscreening sollte zur klinischen…
Wie eine Diät die Darmflora beeinflusst: Krankenhauskeim spielt wichtige Rolle…
DGEM plädiert für Screening und frühzeitige Aufbautherapie: Stationäre COVID-19-Patienten oft…
Führt eine vegane Ernährungsweise zu einer geringeren Knochengesundheit?


Nahrungsergänzungsmittel während der Krebstherapie: Es braucht mehr Bewusstsein für mögliche…
Fusobakterien und Krebs
Fortgeschrittenes Zervixkarzinom: Pembrolizumab verlängert Leben
Krebspatienten unter Immuntherapie: Kein Hinweis auf erhöhtes Risiko für schwere…
Aktuelle Kongressdaten zum metastasierten Mammakarzinom und kolorektalen Karzinom sowie Neues…


Multiple Sklerose: Analysen aus Münster erhärten Verdacht gegen das Epstein-Barr-Virus
Aktuelle Daten zu Novartis Ofatumumab und Siponimod bestätigen Vorteil des…
Multiple Sklerose durch das Epstein-Barr-Virus – kommt die MS-Impfung?
Neuer Therapieansatz für Multiple Sklerose und Alzheimer
„Ich messe meine Multiple Sklerose selbst!“ – Digitales Selbstmonitoring der…


Alexa, bekomme ich Parkinson?
Meilenstein in der Parkinson-Frühdiagnose
Parkinson-Erkrankte besonders stark von Covid-19 betroffen
Gangstörungen durch Kleinhirnschädigung beim atypischen Parkinson-Syndrom
Parkinson-Agenda 2030: Die kommenden 10 Jahre sind für die therapeutische…